Hyperlipoproteinemia Type II
-
Subject Areas on Research
- Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants.
- Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia.
- Apheresis to Mitigate Atherosclerotic Vascular Disease.
- Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country.
- Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry.
- Cholesterol homeostasis in the rat with a portacaval anastomosis.
- Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
- Familial hypercholesterolemia: Detect, treat, and ask about family.
- From the editor: Confronting a pandemic or two.
- Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
- Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.
- Human gene therapy--of tortoises and hares.
- In Reply: Familial hypercholesterolemia: Clarifications.
- Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
- JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product.
- Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.
- Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
- Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
- Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?
- Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.
- Reducing the burden of disease and death from familial hypercholesterolemia: a call to action.
- Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.
- Results and Lessons of a Pilot Study of Cascade Screening for Familial Hypercholesterolemia in US Primary Care Practices.
- Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease.
- Therapy and clinical trials.
- Therapy and clinical trials.
- Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
- US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry.
- Universal Cholesterol Screening in Childhood: A Systematic Review.